UK medical cannabis: potency keeps rising as its price premium narrows
Flower dispensed in England is 35% stronger than in early 2022, from 18.4% to 24.9% THC, while the mix price of a gram only moved from £6.13 to £6.59. Every milligram of THC now costs patients 21% less, origin sets the price of THC more than potency does, and the first list-price cuts are landing on the most potent flower.
Spain ships tens of tonnes of cannabis abroad, yet its patients can only reach two products
Spain authorised 18.3 tonnes of cannabis exports between January and June 2026 — a pace that would finish the year around a fifth above 2025 — while just two preparations sit on the national register created by Royal Decree 903/2025. The constraint is not supply: it is the roll-out of the domestic programme, hospital by hospital, across 353 hospital pharmacy services that are still writing their protocols.
Australia Imports a Record 81 Tonnes as Its Medical Cannabis Market Contracts for the First Time
Australia imported a record 81.1 tonnes of cannabis flower in 2025 and grew another 55.3 tonnes at home — the strongest year on record for both. In the same year, supply to patients fell for the first time since reporting began: units supplied dropped 28.6% in the second half, from 3.72 million to 2.65 million. […]
Germany’s price reset: 52% wiped off pharmacy prices in two years — and still no floor in sight
Retail flower has halved in two years. Canadian import prices are down 28.7% from their peak even as shipment volumes climbed nearly fivefold. And on the wholesale desk, the €2/g line has already broken. In barely two years Germany has gone from the world’s most attractive medical cannabis market to its most price-competitive — and […]
Inside medical cannabis concentrates: hash and rosin reach the international shelf
In May 2026 the United Kingdom listed its first medical hash — Canadian-sourced static hash, crumble and ice-water hash — the clearest sign yet that concentrates are crossing from adult-use shelves into international medical markets. On our tracker that shelf is still gated by GMP-compliant supply, and price follows process, not potency: rosin holds a […]
Germany’s six-month gate: 82% of reimbursed cannabis at risk — and who stands to gain
On 10 July 2026 the Bundestag reshaped Germany’s reimbursed medical cannabis market — striking dried flower from statutory cover and gating extracts, dronabinol and nabilone behind a six-month trial of an approved finished medicine. On our figures that puts roughly €205 million — about 82% of a €248.8 million market — in play. This is […]
Inside Swiss medical cannabis: maturing beyond oils and pain — but who pays?
Switzerland’s 2022 reform made medical cannabis legally accessible to any prescriber, yet two years of federal MeCanna data reveal a market still defined by limited scale rather than open access. Beneath that constrained surface the picture is shifting: a patient base broadening beyond pain, and a product mix moving decisively toward flower. As adult-use pilots […]
Cannabinoids come of age: the clinical-trial pipeline behind Vertanical’s Exilby
Nearly 500 active clinical trials. A 3.5-fold rise in annual trial starts in five years. A decisive pivot away from CBD isolates toward whole-plant, THC-containing medicines aimed at pain. The German authorisation of Vertanical’s Exilby (VER-01) in 2026 — the first high-THC, full-spectrum botanical ever to win pharmaceutical marketing authorisation — is not just a […]
Profitability Arrives as the Access Squeeze Widens — May 2026
Access the full version of this brief with detailed access to the complete recap of the last month, as well as a curated database of market insights and regulation updates. May 2026 sharpened a new imbalance in global cannabis: profitability is finally arriving, while access is tightening at the point of care. In the United […]
UK Medical Cannabis Market Doubles Again — and Flower Loses Share
The UK private medical cannabis market has scaled at a +113% CAGR through 2024. H1 2025 is tracking above 15 tonnes on Q2 run-rate. Behind the headline number, three structural shifts matter: growth rates are decelerating even as volumes still double, product mix is fragmenting beyond flower, and the binding constraints on further scaling are […]